Please login to the form below

Not currently logged in


This page shows the latest Nuplazid news and features for those working in and with pharma, biotech and healthcare.

Acadia’s drive to extend use of Nuplazid hits a wall

Acadia’s drive to extend use of Nuplazid hits a wall

Shares in company down. Acadia Pharmaceutical’s Nuplazid was the first-ever drug to be approved to treat psychosis associated with Parkinson’s disease, but the company’s hopes of extending ... Nuplazid (pimavanserin) is Acadia’s only approved

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest appointments

  • Srdjan Stankovic joins Acadia Pharmaceuticals Srdjan Stankovic joins Acadia Pharmaceuticals

    efforts to explore the full potential of Nuplazid to treat patients suffering from additional CNS disorders.” . ... I look forward to leading the team in advancing the promising development programmes with Nuplazid.".

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...